/Companies

Allinaire Therapeutics

Cleveland, US · Founded 2015 · 3 known investors

Find your way into Allinaire Therapeutics

Sign up to see every warm intro you have to Allinaire Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Allinaire Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases such as COPD and viral-induced acute lung injury. The company was founded on technology licensed from Indiana University.

Founders & leadership

Allinaire Therapeutics was founded in 2015 by Ted Torphy.

TT
Ted TorphyManager
DW
Douglas W.P. HayExecutive
MC
Matthias ClaussScientific Founder
IP
Irina PetracheScientific Founder

Board

SGSamantha Ginther
Samantha GintherBoard directorAssociate at High Alpha
BS
Baiju ShahManager and Chairman
BS
Brian StemmeManager
SJ
Satish JindalBoard director
AB
Arthur BertelsonBoard director

Investors · 3

Reported raises · per SEC filings

Form D private placements

$2.3M disclosed across 2 rounds · 2016–2026

▶$700KraisedApr 2026 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas W.P. HayExecutive Officer, Director
  • Satish JindalDirector
  • Arthur BertelsonDirector
  • Samantha GintherDirector
Offering amount
$700K
Amount sold
$700K
First sale
Jan 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedDec 2018 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ted TorphyDirector
  • Baiju ShahExecutive Officer, Director
  • Brian StemmeDirector
Offering amount
$5M
Amount sold
$1.6M
First sale
Dec 2016
Incorporated
Limited Liability Company, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Allinaire Therapeutics do?
Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases such as COPD and viral-induced acute lung injury. The company was founded on technology licensed from Indiana University.
Who founded Allinaire Therapeutics?
Allinaire Therapeutics was founded by Ted Torphy in 2015.
Who are Allinaire Therapeutics's investors?
Allinaire Therapeutics's investors include Advent Life Sciences, IU Ventures, Crossroads Health Ventures.
How much funding has Allinaire Therapeutics raised?
Allinaire Therapeutics has disclosed $2.3M raised across 2 rounds.
Where is Allinaire Therapeutics headquartered?
Allinaire Therapeutics is headquartered in Cleveland, US.